“…Since over 60% of breast cancer tumors contains estrogen receptors, the discovery of an estrogen receptor specific radiopharmaceutical is desirable. Not surprisingly, tamoxifen has been the target of several radiolabeling studies including 3 H ( , ), 18 F (), 111 In (), 123 I (), 125 I (), and 131 I (), but labeling with 99m Tc has not been reported. Given the widespread use of technetium-99m for radiopharmaceuticals, our previous experience with a radiolabeled tamoxifen, and our recent preparation of an N 2 S 2 bifunctional chelator, the attachment of 99m Tc via a linker from tamoxifen to an N 2 S 2 bifunctional chelator was attempted.…”